BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Cardiovasc Res. 2018 Mar 15;114(4):529-539. doi: 10.1093/cvr/cvy023.
Hypertension is a major risk factor for many common chronic diseases, such as heart failure, myocardial infarction, stroke, vascular dementia, and chronic kidney disease. Pathophysiological mechanisms contributing to the development of hypertension include increased vascular resistance, determined in large part by reduced vascular diameter due to increased vascular contraction and arterial remodelling. These processes are regulated by complex-interacting systems such as the renin-angiotensin-aldosterone system, sympathetic nervous system, immune activation, and oxidative stress, which influence vascular smooth muscle function. Vascular smooth muscle cells are highly plastic and in pathological conditions undergo phenotypic changes from a contractile to a proliferative state. Vascular smooth muscle contraction is triggered by an increase in intracellular free calcium concentration ([Ca2+]i), promoting actin-myosin cross-bridge formation. Growing evidence indicates that contraction is also regulated by calcium-independent mechanisms involving RhoA-Rho kinase, protein Kinase C and mitogen-activated protein kinase signalling, reactive oxygen species, and reorganization of the actin cytoskeleton. Activation of immune/inflammatory pathways and non-coding RNAs are also emerging as important regulators of vascular function. Vascular smooth muscle cell [Ca2+]i not only determines the contractile state but also influences activity of many calcium-dependent transcription factors and proteins thereby impacting the cellular phenotype and function. Perturbations in vascular smooth muscle cell signalling and altered function influence vascular reactivity and tone, important determinants of vascular resistance and blood pressure. Here, we discuss mechanisms regulating vascular reactivity and contraction in physiological and pathophysiological conditions and highlight some new advances in the field, focusing specifically on hypertension.
高血压是许多常见慢性疾病的主要危险因素,如心力衰竭、心肌梗死、中风、血管性痴呆和慢性肾病。导致高血压发展的病理生理机制包括血管阻力增加,这在很大程度上取决于血管直径的减小,原因是血管收缩和动脉重塑导致血管收缩。这些过程受复杂的相互作用系统调节,如肾素-血管紧张素-醛固酮系统、交感神经系统、免疫激活和氧化应激,这些系统影响血管平滑肌功能。血管平滑肌细胞具有高度的可塑性,在病理条件下,其表型从收缩状态转变为增殖状态。血管平滑肌收缩是由细胞内游离钙浓度 ([Ca2+]i) 的增加触发的,促进肌动球蛋白交联的形成。越来越多的证据表明,收缩还受钙非依赖性机制的调节,这些机制涉及 RhoA- Rho 激酶、蛋白激酶 C 和丝裂原激活蛋白激酶信号转导、活性氧和肌动蛋白细胞骨架的重排。免疫/炎症途径和非编码 RNA 的激活也被认为是血管功能的重要调节因子。血管平滑肌细胞 [Ca2+]i 不仅决定了收缩状态,还影响许多依赖钙的转录因子和蛋白的活性,从而影响细胞表型和功能。血管平滑肌细胞信号转导的紊乱和功能的改变影响血管反应性和张力,这是血管阻力和血压的重要决定因素。在这里,我们讨论了在生理和病理生理条件下调节血管反应性和收缩的机制,并强调了该领域的一些新进展,特别是针对高血压。
Cardiovasc Res. 2018-3-15
Arterioscler Thromb Vasc Biol. 2017-12-7
Arterioscler Thromb Vasc Biol. 2016-9
Plants (Basel). 2025-8-12
J Korean Med Sci. 2025-8-25
Pflugers Arch. 2025-7-11
Front Cell Dev Biol. 2025-6-17
J Exp Med. 2017-12-15
Annu Rev Pharmacol Toxicol. 2017-10-2
Mol Ther Nucleic Acids. 2017-9-15
Cardiovasc Res. 2017-7-1
Pulm Pharmacol Ther. 2017-8-4
Front Pharmacol. 2017-5-29